Circulating levels of IL-16 correlate to markers of axonal damage (such as medium and heavy chains of neurofilaments) and cells carrying IL-16 are found in proximity to MS lesions (72), while levels of serum IL-16 drop after successful treatment with IFNβ-1a and was suggested as a marker of clinical response (73). This evidence concerns the gene IL16 and myeloid sarcoma.